Luis Paz Ares

3.0k total citations · 2 hit papers
10 papers, 665 citations indexed

About

Luis Paz Ares is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Luis Paz Ares has authored 10 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Luis Paz Ares's work include Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Luis Paz Ares is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Luis Paz Ares collaborates with scholars based in Spain, United Kingdom and United States. Luis Paz Ares's co-authors include Martin Reck, Monique B. Nilsson, Jonathan W. Goldman, Edward B. Garon, Xiuning Le, Kazuhiko Nakagawa, Katharina Wolff, Carla Visseren‐Grul, Bente Frimodt‐Moller and John V. Heymach and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and European Journal of Cancer.

In The Last Decade

Luis Paz Ares

10 papers receiving 659 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

2022 296 citations Byoung Chul Cho, Delvys Rodríguez‐Abreu et al. The Lancet Oncology profile →
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

2020 228 citations Xiuning Le, Monique B. Nilsson et al. Journal of Thoracic Oncology profile →

Peers

Luis Paz Ares

ONCOL

PRM

MB

IMMUN

CR

Elaine Shum United States

Hidenori Mizugaki Japan

Santiago Ponce Aix Spain

Joao V. Alessi United States

Peijian Peng China

Elvire Pons‐Tostivint France

Gataree Ngarmchamnanrith United States

Xianping Yi China

Angel Qin United States

Gen Lin China

Elaine Shum United States

Luis Paz Ares

388 ×0.8

ONCOL

348 ×1.3

PRM

176 ×0.9

MB

78 ×0.5

IMMUN

69 ×0.7

CR

Citations per year, relative to Luis Paz Ares Luis Paz Ares (= 1×) peers Elaine Shum

Countries citing papers authored by Luis Paz Ares

Since Specialization

Citations

This map shows the geographic impact of Luis Paz Ares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Paz Ares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Paz Ares more than expected).

Fields of papers citing papers by Luis Paz Ares

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Paz Ares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Paz Ares. The network helps show where Luis Paz Ares may publish in the future.

Co-authorship network of co-authors of Luis Paz Ares

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Paz Ares. A scholar is included among the top collaborators of Luis Paz Ares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Paz Ares. Luis Paz Ares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Cho, Byoung Chul, Delvys Rodríguez‐Abreu, Maen Hussein, et al.. (2022). Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. The Lancet Oncology. 23(6). 781–792. 296 indexed citations breakdown →

2.

Früh, Martin, Cédric Panje, Martin Reck, et al.. (2020). Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts. Lung Cancer. 146. 6–11. 11 indexed citations

3.

Le, Xiuning, Monique B. Nilsson, Jonathan W. Goldman, et al.. (2020). Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. Journal of Thoracic Oncology. 16(2). 205–215. 228 indexed citations breakdown →

4.

Garrido, Pilar, M.E. Olmedo, Ana Gómez, et al.. (2017). Treating KRAS-mutant NSCLC: latest evidence and clinical consequences. Therapeutic Advances in Medical Oncology. 9(9). 589–597. 32 indexed citations

5.

Socinski, Mark A., Frederic J. Kaye, David R. Spigel, et al.. (2016). Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. Clinical Lung Cancer. 18(1). 68–76.e2. 67 indexed citations

6.

Maroto, Pablo, Robert Huddart, Xavier García del Muro, et al.. (2011). Brief Report: Phase II Multicenter Study of Temozolomide in Patients with Cisplatin-Resistant Germ Cell Tumors. Oncology. 80(3-4). 219–222. 6 indexed citations

7.

Markman, B., Carlos Gomez‐Roca, Andrés Cervantes, et al.. (2010). Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti- EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).. Journal of Clinical Oncology. 28(15_suppl). 2522–2522. 6 indexed citations

8.

García‐Carbonero, Rocio, et al.. (2009). Evaluation on the IGF-IR Inhibitor CP-751,871, alone and in combination with paclitaxel in lung and colon cell lines. Journal of Clinical Oncology. 27(15_suppl). e22125–e22125. 1 indexed citations

9.

Dómine, Manuel, Mariano Provencio, Christian Rolfo, et al.. (2007). P3-080: Erlotinib as single agent in men with advanced or metastatic NSCLC: A retrospective analysis. Journal of Thoracic Oncology. 2(8). S712–S713. 2 indexed citations

10.

Caponigro, Francesco, Christian Dittrich, Jakob B. Sørensen, et al.. (2002). Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. European Journal of Cancer. 38(1). 70–74. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact